Table 2.
Characteristics of the TB datasets used to profile COVID-19 risk from COVID-19 immune cell and pathway signatures
| Dataset | Setting | Samples included | Study design | Population | Sampling | TB case definition | Follow-up duration and method |
|---|---|---|---|---|---|---|---|
| TB contacts cohort (TCC) (Singhania et al., 2018) |
London, UK | 54 (21 active TB, 33 LTBI non-progressors) | Cohort | HIV-negative adults (18–78 years) TB cases and TB contacts | Baseline | TB: Culture confirmed or clinically diagnosed LTBI: QFT positive |
1.9 years (IQR, 1.7–2.2) |
| Cape Town, South Africa | 47 (16 active TB, 31 LTB non-progressors I) | ||||||
| Leicester, UK | 313 (53 active TB, 23 progressors, 118 LTBI non-progressors, 119 healthy non-progressors) |
Cohort | HIV-negative individuals (16–84 years) TB cases and TB contacts | Baseline plus serial for a sub-set | TB: Culture-confirmed or GeneXpert MTB/RIF positive LTBI: QFT positive | 13 months, active | |
| Adolescent cohort study (ACS) (Zak et al., 2016) | Cape Town, South Africa | 355 (110 progressors, 245 matched non-progressors) | Nested case-control | HIV-negative adolescents (12–18 years) with latent TB infection | Serial (0, 6, 12, and 24 months) | TB: Intrathoracic disease with 2 positive smears or 1 positive culture LTBI: QFT positive |
2 years, active |
| Grand Challenges 6 (GC6) (Suliman et al., 2018) | The Gambia South Africa Ethiopia |
412 (98 progressors, 314 matched non-progressors) | Nested case-control | HIV-negative individuals (8–60 years) household pulmonary TB contacts | Serial (0, 6, and 18 months) | TB: Culture confirmed or clinically diagnosed LTBI: QFT positive |
2 years, active |
LTBI, latent TB infection; QFT, QuantiFERON-TB. See also Figure S2.